BRCA1/2 mutations had been related to a better pathologic full response fee in sufferers with early-stage TNBC handled with a de-escalated chemotherapy routine.
Amongst sufferers with early-stage triple-negative breast most cancers (TNBC), present process chemotherapy remedy with deescalated neoadjuvant nab-paclitaxel plus carboplatin was discovered to be more practical than nab-paclitaxel plus gemcitabine, researchers have discovered. Researchers famous {that a} useful pathologic full response (pCR) fee was seen amongst sufferers with and with out BRCA1 and/or BRCA2 mutations, however the influence was discovered to be extra pronounced amongst sufferers with these mutations.
The findings are from a preplanned secondary evaluation of the part 2 ADAPT-TN scientific trial carried out by the West German Research Group (WSG) between June 2013 and February 2015, with genetic evaluation carried out between January 2018 and March 2020 with ultimate information evaluation happening in September 2023. The findings had been revealed in JAMA Community Open.
The research, as an professional defined to CURE, was carried out previous to the fashionable period of immunotherapy therapies.
“As this research was maturing, the complete normal care has shifted,” defined Dr. Yuan Yuan. Yuan is a professor of drugs, director of breast oncology and medical director of breast most cancers analysis at Cedars-Sinai Medical Heart in Los Angeles, in addition to a well being sciences scientific professor at UCLA. She emphasised the significance of the findings of the part 3 KEYNOTE-522 scientific trial, which started in 2017 and noticed sufferers with beforehand untreated stage 2 or 3 TNBC handled with neoadjuvant Keytruda (pembrolizumab) plus paclitaxel and carboplatin.
Glossary:
Neoadjuvant: administered previous to the primary remedy, comparable to surgical procedure.
Pathologic full response: the dearth of all indicators of most cancers in tissue samples eliminated throughout surgical procedure or biopsy after remedy with radiation or chemotherapy, in accordance with the Nationwide Most cancers Institute.
Somatic: an alteration in DNA that happens after conception, in accordance with the Nationwide Most cancers Institute.
Pathogenic variants: adjustments within the DNA sequence of a gene that causes an individual to have or be vulnerable to creating a sure genetic dysfunction or illness, comparable to most cancers, in accordance with the Nationwide Most cancers Institute.
Knowledge from that trial revealed in The New England Journal of Drugs confirmed that, at a median follow-up of 15.5 months, sufferers within the Keytruda group achieved a pCR fee of 64.8% in contrast with 51.2% in sufferers who obtained placebo plus chemotherapy. Findings from the trial led to the FDA’s approval of Keytruda plus chemotherapy for sufferers with high-risk, early-stage TNBC in 2021.
“So, [ADAPT-TN) is prior to the immunotherapy era. It has its own limitation, and the fact that having a BRCA mutation will yield a better benefit from chemoimmunotherapy has been documented in other studies,” Yuan said. “So I think the take-home message is, yes, the somatic mutation of BRCA1 and 2 may have a better responses using a neoadjuvant platinum-containing regimen. But the study itself, we have to review that in the current clinical context, which has already changed.”
Yuan cited prior studies, such as:
- Findings published in npj Breast Cancer in 2024, which showed that among patients with stage 1 to 3 TNBC who received carboplatin, 46% of BRCA1 carriers achieved pCR, versus 33% of BRCA2 carriers and 30% of noncarriers.
- Additionally, findings published in Cancers in 2022 showed that, among patients with TNBC treated with neoadjuvant chemotherapy, 59% of patients with germline BRCA1/2 mutations achieved pCR, versus 34% of noncarriers.
- Furthermore, a meta-analysis published in Breast in 2022 stated that a BRCA1/2 mutation was associated with a 17.6% increase in pCR rate.
Researchers performed tumor next-generation sequencing analyses for 266 patients in the ADAPT-TN study, all of whom were female, with a median age of 51 years. BRCA1 and/or BRCA2 tumor pathogenic variants (tPVs) were found in 42 patients, or 15.8% of patients. When compared with patients without BRCA1/2 mutations patients with those mutations were younger (median age 46.5 versus 53 years) and were more frequently premenopausal (66.7% versus 43.3%), researchers noted.
Nineteen of the 42 patients (45.2%) with BRCA1/2 mutations experienced a pCR, versus 77 of 224 patients (34.4%) without the mutation. Patients in the BRCA1/2 carboplatin subgroup had a pCR rate of 64.3%, or nine of 14 patients, which was higher than all others pooled together — 34.5%, or 87 of 252.
“The finding of the study is not surprising,” Yuan said. “It verifies that the BRCA1 and 2 carriers do tend to have a higher pCR rate.”
While ADAPT-TN researchers argue that their findings may support BRCA1/2 tPV status as a stratification factor for chemotherapy de-escalation in order to prevent overtreatment, Yuan said she would not suggest that.
“I think the pCR rate is not really overwhelmingly high enough to de-escalate in my in my honest opinion,” she said.
Reference:
“Genetic Alterations, Therapy Response, and Survival Among Patients With Triple-Negative Breast Cancer: A Secondary Analysis of a Randomized Clinical Trial” by Dr. Lisa Richters, et al., JAMA Network Open.
For more news on cancer updates, research and education, don’t forget to subscribe to CURE®’s newsletters here.
